logo
Plus   Neg
Share
Email

BioNTech Discloses Addl Details Of Pfizer Collaboration On COVID-19 Vaccine

BioNTech (BNTX) disclosed additional details of an collaboration with Pfizer Inc. (PFE) to advance candidates from BioNTech's mRNA vaccine program.

The collaboration aims to rapidly advance multiple COVID-19 vaccine candidates into human clinical testing based on BioNTech's proprietary mRNA vaccine platform.

As per the terms of the agreement, Pfizer will pay BioNTech $185 million in
upfront payments, including a cash payment of $72 million and an equity
investment of $113 million.

BioNTech is eligible to receive future milestone payments of up to $563 million for a potential total consideration of $748 million. Pfizer and BioNTech will share development costs equally.

Initially, Pfizer will fund 100 percent of the development costs, and BioNTech will repay Pfizer its 50 percent share of these costs during the commercialization of the vaccine.

The two companies plan to jointly conduct clinical trials for the COVID-19 vaccine candidates initially in the United States and Europe across multiple sites. BioNTech and Pfizer intend to initiate the first clinical trials as early as the end of April 2020, assuming regulatory clearance.

BioNTech and Pfizer will also work jointly to commercialize the vaccine worldwide, excluding China, which is already covered by BioNTech's collaboration with Fosun Pharma, upon regulatory approval.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients. The U.S. federal government's General Services Administration or GSA has awarded a five-year federal transportation contract, estimated to be worth up to $810 million, to Uber Technologies Inc. and Lyft Inc., according to multiple reports. Under the contract, the ride-hailing companies would provide services to various public agencies and their around 4 million employees across the nation.
Follow RTT